Get started
Author

Mylène Wespiser

Uveal melanoma: In the era of new treatments
2023 · M. Wespiser, E. Neidhardt, et al. · Cancer Treatment Reviews · 54
Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer
2025 · Mylène Wespiser, Romane Gille, et al. · Expert Opinion on Investigational Drugs · 18
Treatment sequences in EGFR mutant advanced NSCLC
2024 · M. Wespiser, A. Swalduz, et al. · Lung Cancer · 16
PDF
Chemotherapy to potentiate the radiation-induced immune response
2023 · Benoît Lecoester, Mylène Wespiser, et al. · International review of cytology · 5
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al. · Cancer Research Communications · 4
PDF
SO-20 Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
2022 · A. Vienot, D. Vernerey, et al. · Annals of Oncology · 4
Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4+ Th1 Response in Metastatic Non–Small Cell Lung Cancer
2023 · Mylène Wespiser, Amélie Marguier, et al. · Journal of Immunotherapy · 3
ROS1-positive non-small cell lung cancer: from genomics to treatment decisions
2026 · Mylène Wespiser, Romane Gille, et al. · Frontiers in Oncology · 1
PDF
8P STC1, a baseline predictive biomarker for overall survival in metastatic colorectal cancer (mCRC)
2020 · M. Wespiser, J. Henriques, et al. · Annals of Oncology · 1
ctDNA-based detection of residual disease: implications for management of non-metastatic NSCLC
2026 · Charline Leclercq, Mylène Wespiser, et al. · Frontiers in Oncology
PDF
Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception
2026 · Mylène Wespiser, Pauline Rochefort, et al. · Cancer Treatment Reviews
Impact des recommandations de prise en charge de la maladie thrombo-embolique veineuse de 2019 et 2021 sur l'utilisation des AOD chez les patients atteints de cancer
2026 · Romain VARNIER, François BETTEGA, et al. · Journal of Epidemiology and Population Health
Figure S3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
TIE-2–Expressing Monocytic Myeloid-Derived Suppressor Cells Are Involved in Resistance to Anti–PD-1 Therapy Mediated by Angiopoietin 2 in Patients with Melanoma
2025 · Amélie Marguier, Jessica Mathiot, et al. · Journal of Investigative Dermatology
Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure S1 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Supplementary Data from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure 2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure S4 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure 3 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Figure S2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
2025 · Angélique Vienot, Dewi Vernerey, et al.
Works count: 36
Citation count: 106
H-index: 4
I10-index: 3
Year
Topic
Type